Related Experiment Videos
Management of atrial fibrillation: out-of-hospital approach
1Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Insights
Atrial fibrillation management involves assessing hospitalization needs, controlling heart rate, and determining anticoagulation based on stroke risk factors. Warfarin is recommended for high-risk patients, while aspirin may be used for others, with careful monitoring for older adults.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Atrial fibrillation (AF) is a common condition, particularly in older adults, and a significant cause of stroke.
- Effective management of AF is crucial to prevent cerebrovascular events and improve patient outcomes.
Purpose of the Study:
- To outline the diagnostic and therapeutic strategies for managing patients presenting with atrial fibrillation.
- To guide physicians in determining the necessity of hospitalization, rate control, and anticoagulation therapy.
Main Methods:
- Clinical assessment including history, physical examination, and electrocardiogram to determine hospitalization needs.
- Evaluation of risk factors for thromboembolism (e.g., age, heart failure, hypertension) using echocardiography.
- Assessment of heart rate control goals and pharmacological interventions (e.g., digoxin, beta-blockers, calcium channel blockers).
Main Results:
- Hospitalization is indicated for signs of infarction, heart failure, hypotension, excessive rate, pre-excitation, or recent onset (<48 hours) requiring cardioversion.
- Target heart rates are <90 bpm at rest and <120 bpm after exercise.
- Warfarin is recommended for patients with one or more risk factors for stroke, with careful INR monitoring in those over 65. Aspirin is an alternative for lower-risk patients.
Conclusions:
- Management of atrial fibrillation requires a stepwise approach to hospitalization, rate control, and stroke prevention.
- Risk stratification is key to selecting appropriate anticoagulation therapy (warfarin or aspirin).
- Long-term anticoagulation with warfarin is generally recommended for high-risk individuals, while cardioversion may be considered in specific scenarios.
Abstract:
Atrial fibrillation is increasingly common with advancing age and is responsible for 10% of the half-million strokes that occur annually in the United States. When a patient presents with atrial fibrillation, the physician's first task is to use the history, physical examination, and electrocardiogram to determine whether hospitalization is necessary. Factors indicating a need for hospital care include evidence of infarction or ischemia, congestive heart failure, hypotension or hypoperfusion, excessive rate, or pre-excitation. In addition, if the episode began within 48 hours, consider early cardioversion, which also requires hospitalization. Next, the need for control of the ventricular rate should be assessed. A heart rate under 90 beats/min at rest and under 120 beats/min after 1 minute of step exercise is a reasonable goal. Dixogin usually controls the resting rate, but sometimes beta-blockers or calcium channel blockers are needed to control the exercise rate. The need for anticoagulation is determined by the presence of clinical risk factors such as valvular heart disease, previous thromboembolism, hypertension, age over 65 years, congestive heart failure, and left atrial enlargement. An echocardiogram is necessary to complete this assessment. Patients having one or more of these risk factors are most effectively treated with warfarin, as evident from several clinical trials. Although patients over age 65 demonstrate reduced thromboembolism with warfarin therapy, they also are more prone to cerebral hemorrhage, thus, their international normalization ratio (INR) should be kept at the lower end of the therapeutic range [2,3]. Other patients can be treated with aspirin, although stroke reduction in these patients may be more related to reduction of arterial thrombosis than thromboembolism. Patients under age 65 with no risk factors have a very low annual risk of stroke without therapy (approximately 1%). If symptoms persist or if this is a first episode in someone without left atrial enlargement, cardioversion can be considered after 3 weeks of warfarin therapy with INR in the therapeutic range. Otherwise, warfarin should be continued indefinitely. Prevention of recurrence with antiarrhythmic drugs is somewhat problematic because of incomplete efficacy (30% recurrence at 1 year) and the potential for inducing other, life-threatening arrhythmias.